Interview with Jean Paul Scheuer, General Manager, Sanofi Ukraine
What were the factors that led to Sanofi’s decision to establish an LLC in 2009 in Ukraine, and how has it changed your operations? Most of the major foreign companies…
Address: 48-50A, st. Zhylyanska
Business Center Prime,
01033, Kyiv, Ukraine
Tel: +380 044 354 20 00
Web: http://www.sanofi.ua/l/ua/index.jsp
Sanofi S.A. is a multinational pharmaceutical company headquartered in Paris, France, the world’s fourth-largest by prescription sales. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. Sanofi is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo. It changed its name to Sanofi in May 2011.
The company covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world’s largest producer of the latter through its subsidiary Sanofi Pasteur).
What were the factors that led to Sanofi’s decision to establish an LLC in 2009 in Ukraine, and how has it changed your operations? Most of the major foreign companies…
Following Takeda’s acquisition of Nycomed earlier this year, how has the transaction affected your operations in Ukraine and what synergies were generated by it? Regarding the integration process, we are…
As the founder of SMD what was it the prompted you to create this company and what were your objectives at that time? Up until 2003 when I created SMD,…
What was the market need that spawned the creation of AIPM in 2009 considering that there were already other trade associations in Ukraine that were representing the interests of international…
Lekhim group was one of the pioneers for establishing a national pharmaceutical industry in 1992. This year you will be celebrating 20th anniversary. Would you start by providing us with…
If you could provide our readers with your philosophy when you founded Sayenko Kharenko in 2004. What were the market needs that were perhaps missing that you identified and wanted…
It has been one year since you were appointed as the head of UCB’s operations in Ukraine. What was the mission of your assignment when you took this position and…
Considering you only took over as CEO from your father in 2009, what was the mandate that was given to you as new CEO of the company – including your…
Orion’s global strategy focuses on the CIS and Eastern European markets that still exhibit large growth potential and are expanding, despite a reverse trend for the rest of the industry.…
What were the factors that led to Sanofi’s decision to establish an LLC in 2009 in Ukraine, and how has it changed your operations? Most of the major foreign companies…
Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian…
Since the establishment of Astellas’ predecessor Brocade in Russia in 1992, what has been Astellas’ evolution in Ukraine? Astellas has been present in Ukraine for 16 years, first as Yamanouchi…
See our Cookie Privacy Policy Here